Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:14 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety and Efficacy Study of Urokinase for the Treatment of Diabetic Foot Syndrome and Critical Limb Ischemia
NCT01638585 · GWT-TUD GmbH · PHASE3 · terminated · last registry update 2014-04-07 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “recruition number was not reached” | – | Registry record, GWT-TUD GmbH |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PLAU within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2015-03-13Also stopped (terminated): medac GmbH, Urokinase (NCT00823225)
- 2014-07-17Results posted on the registry: Gynecologic Oncology Group, Urokinase-Derived Peptide A6 (NCT00939809)
- 2014-06-18Phase 3 first posted: Queen Fabiola Children's University Hospital, insertion of a chest drain with urokinase instillation (NCT02165891)
- 2014-01-14Phase 3 first posted: Universitair Ziekenhuis Brussel, Taurolidine Urokinase + Taurolidine Heparin (NCT02036255)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision